Medical Mycology Journal
Reviews
Diagnosis and Treatment of Mucormycosis in Patients withHematological Malignancies[Translated Article]
Yuki Asano-Mori
著者情報
ジャーナル フリー

58 巻 (2017) 3 号 p. E97-E105

詳細
PDFをダウンロード (170K) 発行機関連絡先
抄録

The risk of invasive fungal infections (IFIs) is extremely high in patients with hematological malignancies due to the prolonged and profound neutropenia and immunosuppression after chemotherapy and hematopoietic stem cell transplantation. There has been increasing interest in mucormycosis despite its relatively uncommon occurrence, because occasional breakthrough infections have been observed under anti-Aspergillus prophylaxis. The aggressive nature of mucormycosis easily leads to high mortality because of delays in diagnosis and incorrect treatment decisions, which are due in part to lack of adjunctive diagnostic tools and having similar clinical and radiological features with invasive aspergillosis. The only currently available antifungals against Mucorales in Japan are amphotericin B formulations. Thus, comprehensive therapeutic strategies, including surgery, should be considered to achieve a successful outcome.

著者関連情報
© 2017 The Japanese Society for Medical Mycology
前の記事 次の記事

閲覧履歴
feedback
Top